Certainly! Chronic Myelomonocytic Leukemia (CMML) is a type of blood cancer that is relatively rare, with about 1,100 diagnoses each year in the United States. Here are some key points about CMML:
- **Prevalence and Demographics**: CMML is more common in older adults, with about 90% of cases diagnosed in individuals who Show Full Answer
Certainly! Chronic Myelomonocytic Leukemia (CMML) is a type of blood cancer that is relatively rare, with about 1,100 diagnoses each year in the United States. Here are some key points about CMML:
- **Prevalence and Demographics**: CMML is more common in older adults, with about 90% of cases diagnosed in individuals who are at least 60 years old. Men are twice as likely to develop CMML compared to women.
- **Disease Characteristics**: CMML develops from monocytes, which are a type of white blood cell important for immune system function. There are different subtypes of CMML, which can affect symptoms and outcomes.
- **Prognosis Factors**: Several factors influence the prognosis of CMML, including age, other health conditions, blood cell counts, genetic changes in CMML cells, and levels of lactate dehydrogenase (LDH) in the blood.
- **Survival Rates**: The survival rates vary by subtype:
- About 20% of people with type 0 or 1 CMML live for five years or more after being diagnosed.
- About 10% of people with type 2 CMML live for five years or more after diagnosis.
- **Progression to AML**: A significant percentage of CMML patients may develop Acute Myeloid Leukemia (AML) over time. The likelihood varies based on the subtype of CMML:
- About 15% to 30% of all CMML patients may develop AML.
- Specifically, about 18% of type 0 or 1 CMML patients and about 63% of type 2 CMML patients are diagnosed with AML within five years.
These details should provide a comprehensive overview of Chronic Myelomonocytic Leukemia. If you need more specific information or have other questions, feel free to ask!
May 9, 2024
Join
Your Privacy Choices
